GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.
A novel first-in-class small molecule (ERX-11) that interacts with and disrupts the interactome of the estrogen receptor (ER), blocks the growth of ER-positive breast cancers, including those that are resistant to currently approved hormonal agents.
A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.
Editors' Summary: This Replication Study has reproduced some parts of the original paper but it also contains results that are not consistent with other parts of the original paper.
The tubulin GTPase cycle structurally modulates the microtubule cap, causing lattice expansion, which is an intermediate state involved in phosphate release and regulatory signaling.
A model of in vitro human corticogenesis identifies alterations in gene expression caused by loss of 16p11.2 CNV genes in hiPSC-derived progenitor cells.
The mechanism is revealed that connects the protein degradation machinery to cellular membrane-bound compartments during proteostasis stress in mammalian cells.
